OraSure Technologies (NASDAQ:OSUR) Posts Earnings Results, Beats Expectations By $0.05 EPS

OraSure Technologies (NASDAQ:OSUR) posted its quarterly earnings data on Monday. The medical instruments supplier reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.05, FiscalAI reports. OraSure Technologies had a negative return on equity of 19.09% and a negative net margin of 43.70%. The firm had revenue of $30.91 million during the quarter, compared to analysts’ expectations of $31.00 million.

OraSure Technologies Price Performance

OraSure Technologies stock traded up $0.09 during trading hours on Monday, hitting $3.53. 744,341 shares of the stock traded hands, compared to its average volume of 557,322. The firm’s 50 day moving average price is $3.73 and its 200-day moving average price is $3.53. The stock has a market capitalization of $243.46 million, a price-to-earnings ratio of -5.12 and a beta of 1.08. OraSure Technologies has a 1 year low of $2.08 and a 1 year high of $4.58.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of OraSure Technologies in a research note on Tuesday, September 1st. Zacks Research upgraded shares of OraSure Technologies to a “hold” rating in a research note on Friday, October 2nd. Craig Hallum upgraded shares of OraSure Technologies to a “strong-buy” rating in a research note on Friday, October 23rd. Finally, Wall Street Zen raised shares of OraSure Technologies from a “sell” rating to a “hold” rating in a research report on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $3.00.

About OraSure Technologies

OraSure Technologies, Inc develops, manufactures and markets diagnostic products and specimen-collection technologies used by healthcare providers, laboratories, researchers and consumers. The company focuses on making testing more accessible through products that support decentralized, point-of-care and at-home testing, as well as laboratory-based molecular and diagnostic workflows.

Its portfolio has included the OraQuick line of rapid diagnostic tests, including oral-fluid tests for HIV and hepatitis C, along with other infectious-disease testing products.